OCD Trial Flop Disappointment for Transcept Pharmaceuticals
By Catherine Shaffer
Wednesday, December 26, 2012
Top-line results from a Phase II trial of TO-2061, for obsessive compulsive disorder, were a let-down for Transcept Pharmaceuticals Inc., of Point Richmond, Calif. The data showed that TO-2061 failed to meet its primary efficacy endpoint of improving OCD symptoms compared to placebo.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.